multipl recent acquisit bolster trajectori reiter buy rais target
recent stock weak appear unwarr view
recent drift downward biolif share appear unjustifi given
compani recent busi initi notabl acquisit
savsu astero bio custom biogen system cb share
roughli sinc late septemb time
frame xbi view weak
may driven compani top-lin revenu
came vs origin estim howev
believ top-lin revenu still rel
respect vs previou estim
increas top-lin revenu project vs
prior driven mainli contribut astero bio cb
base anticip contribut astero savsu cb
continu growth media revenu manag expect
total revenu repres growth
vs midpoint revenu guidanc consid context
believ recent down-drift share constitut potenti
opportun accumul attract entri point would
anticip rebound near-term accordingli reiter buy rate
rais price target previou
per share
multipl revenu driver evid recently-report
quarter biolif indic gain new cell gene therapi
custom process new cross-refer request fda
master file cryostor hypothermosol estim
use custom clinic applic world-wide
fisher rate vwr world courier quickstat demand
biolif proprietari biopreserv media product new
exist custom continu show strength biolif
process roll new thawstar cb autom thaw product
large-volum cell gene therapi frozen cryobag savsu
also appear firm footingsinc januari evo
cold chain system use initi shipment
cell gene therapy-focus firm recent evo custom includ
adaptimmun adap rate janssena divis johnson
johnson rate kbi pharma nanj legend tessa
therapeut manag estim evo product
revenu would rang base anticip growth
deploy fleet evo shipper princip specialti courier
serv cell gene therapi industri
custom biogen system like rapid contributor mid-
novemb biolif announc acquir asset
custom biogen system inc cb privately-held compani
oper locat near detroit mi cb global leader
design manufactur state-of-the-art liquid nitrogen laboratori
freezer cryogen equip also offer relat cloud-bas
monitor system continu assess biolog sampl storag
condit alert equip owner fault condit occur
revenu slate accord data
market research world-wide demand liquid nitrogen freezer
storag product estim exceed
definit distribut analyst rate analyst certif disclosur pleas refer page report
multipl strateg advantag cb acquisit biolif expect sever near-term benefit cb acquisit
includ sale market leverag would optim exist relationship among custom base lead cell
gene therapi compani regen medicin market cb advanc liquid nitrogen freezer play critic role
safe storag high-valu start materi manufactur cell gene therapi product order reduc relianc
non-u supplier lower cost biolif plan leverag cb engin manufactur expertis provid
certain hardwar compon evo cold chain manag system note biolif paid john brother founder
chief execut sole stockhold cb cash worth biolif common stock furthermor mr brother
may earn total addit mileston cash stock next five year base exceed certain
annual new product revenu goal believ acquisit price paid reason given current cb revenu
run rate anticip multipl sourc synergi realiz near-term
valuat risk valu biolif base discount cash flow dcf -driven methodolog assum
discount rate termin growth rate effect tax rate yield enterpris valu total firm valu
assum roughli cash deriv target per share base fully-
dilut share outstand risk includ limit inabl improv oper effici
go forward over-reli individu custom particularli distribut segment neg fallout
regulatori setback product candid biolif manufactur reagent provid inabl consumm
capital-effici accret transact competit pressur larger reagent supplier
thousand except per share data
compani report wainwright co estim
servic revenue- research other- total expensescost product servic research sell gener acquisit costs- amort intangibles- total loss income/expenseinterest interest amort debt discount- loss equity-method invest acquisit savsu- loss dispos assets- incom expens net- total invest incom incom loss provis incom defer incom tax benefit- prefer stock net net loss per share net loss per share weight averag number share outstand weight averag number share outstand inc
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc blfs-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl decemb
 wainwright co llc firm member finra sipc regist broker-deal
raghuram selvaraju ph certifi view express report accur reflect person view
subject secur issuer discuss part compens directli indirectli
relat specif recommend view express research report neither member
household offic director advisori board member compani
none research analyst research analyst household financi interest secur
inc includ without limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc non-invest bank servic previou
firm affili receiv compens inc invest bank servic within twelv
month seek compens compani mention report invest bank servic within
three month follow public research report
firm make market inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
